LIPELLA PHARMACEUTICAL

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

24 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

22 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

21 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

12 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

01 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

01 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

29 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

31 May 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

29 May 2024 08:00:00 By Nasdaq GlobeNewswire

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

21 May 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

17 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

05 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

03 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

20 Feb 2024 08:00:48 By Nasdaq GlobeNewswire

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

20 Dec 2023 08:00:00 By Nasdaq GlobeNewswire